Immune-Mediated Inflammatory Disease Forum

Ogdie et al. reported that safety findings were consistent with the known profile of guselkumab in patients with psoriatic disease. Learn more here by Ogdie et al.: ow.ly/pumq50YvfBU #IMIDForum

Our latest #UC literature highlights, featuring research by Panaccione et al., are now live on the #IMIDForum. Access these comprehensive slide decks for the latest insights in #IBD treatment: imidforum.com/publications/8…

At Week 104, Ramiro et al. observed greater improvements in some outcomes in patients with ≤5 years versus >5 years of symptoms, although this cannot be definitively attributed to bimekizumab without a PBO comparator. Access the full summary slides here: ow.ly/cZ0750YviXq

Looking for the latest insights in #IBD? Our new slide deck and literature highlights are live on the #IMIDForum. Access these valuable resources today: ow.ly/CrEN50YFyqQ

Discover the newest findings in #RA in our latest literature highlights. Enhance your clinical knowledge with free access on the #IMIDForum: imidforum.com/literature-rev…

Clinical data suggest that progression of latent TB infection to active disease during PsO treatment with IL-17is or IL-23is is rare. Learn more from Blauvelt et al. here: ow.ly/kccb50YCfg2

Our latest #RA podcast episode is now available on the #IMIDForum! Stay up to date with the newest research and clinical insights. Stream for free today, wherever you get your podcasts!: imidforum.com/podcasts/episo…

Kao et al. found that b/tsDMARD treatment class did not affect malignancy risk for patients with RA, though some clinical characteristics did See more here: ow.ly/ufy650Yza5Y #IMIDForum

👉 Our April literature search identified 65 new papers in #PsO! 👀 View the results by clicking the link below: imidforum.com/resources

Learn the latest in the field of #RA with March publication highlights now available via the #IMIDForum imidforum.com/literature-rev…

👉 Our April literature search identified 32 new papers in #IBD! 👀 View the results by clicking the link below: imidforum.com/resources

Dive into the latest research on #dermatology with our new in-depth slide decks and literature highlights! Available now for free on the #IMIDForum: ow.ly/oV9m50YCf0z

Ixekizumab treated patients exhibited longer disease duration and more prior experience with b/tsDMARD treatment, while those who initiated a TNFi or secukinumab 150mg exhibited shorter disease duration. Learn more here by Marzo-Ortega et al.: ow.ly/Y08j50YvfzA #IMIDForum

This month on the #IMIDForum, you can find the latest axSpA summary slide decks and literature highlights to view or download. Head over now to keep yourself up to date. ow.ly/foQq50YviVJ

EULAR proposed consensus definitions of difficult-to-manage PsA and treatment-refractory subgroups reported by Marzo-Ortega et al. should now be applied in well-designed observational, interventional clinical trials and basic science research studies in PsA populations. Learn more here: ow.ly/YoIV50Yvfx0 #IMIDForum

Ouali et al. reported that older age and higher disease activity were significantly associated with treatment switching in patients with axSpa. Learn more on the #IMIDForum: ow.ly/34ET50YviSz

A study of 12 European national registries found that some EMA and FDA warnings on JAKi safety led to fluctuations in prescription rate for patients with RA. See more details on Mongin et al.’s findings on the IMID Forum here: ow.ly/4pPU50Yz2Ne #IMIDForum

Our latest #dermatology slide deck and literature highlights are now available on the #IMIDForum! Stay up to date with the newest research and clinical insights. Access them for free today: imidforum.com/literature-rev…

Blauvelt et al. reviewed evidence on safety of IL-17i and IL-23i in the setting of latent TB infection and provided a new Joint Position Statement on this topic. Dive into the data here: ow.ly/LSwP50YCeTZ

Looking for the latest insights in #PsA? Our new slide deck and literature highlights are live on the #IMIDForum. Access these valuable resources today: ow.ly/4Zr650YvcCK